The usefulness of fecal calprotectin in assessing inflammatory bowel disease activity

다국어 초록 (Multilingual Abstract)

Background/Aims: Fecal calprotectin (FC) is known to correlate with disease activity and can be used as a predictor for relapse or treatment response in inflammatory bowel disease (IBD). We evaluated the usefulness of FC as a biomarker for disease activity in patients with IBD using both enzyme-linked immunosorbent assay (ELISA) and a quantitative point-of-care test (QPOCT).
Methods: Fecal samples and medical records were collected from consecutive patients with IBD. FC levels were measured by both ELISA and QPOCT and patient medical records were reviewed for clinical, laboratory, and endoscopic data.
Results: Ninety-three patients with IBD were enrolled, 55 with ulcerative colitis (UC) and 38 with Crohn’s disease (CD). The mean FC-ELISA levels were 906.3 ± 1,484.9 μg/g in UC and 1,054.1 ± 1,252.5 μg/g in CD. There was a strong correlation between FC-ELISA level and clinical activity indices (p < 0.05). FC-ELISA level was significantly lower in patients with mucosal healing (MH) compared to those without MH in UC (85.5 ± 55.6 μg/g vs. 1,503.7 ± 2,129.9 μg/g, p = 0.005). The results from the QPOCT corresponded well to those from ELISA. A cutoff value of 201.3 μg/g for FC-ELISA and 150.5 μg/g for FC-QPOCT predicted endoscopic inflammation (Mayo endoscopic subscore ≥ 1) in UC with a sensitivity of 81.8% and 85.8%, respectively, and a specificity of 100% for both.
Conclusions: FC was strongly associated with disease activity indices, serologic markers, and endoscopic activity in patients with IBD. QPOCT can be used more conveniently than ELISA to assess FC in clinical practice.

참고문헌 (Reference)

1 Smith LA, "Utility of faecal calprotectin analysis in adult inflammatory bowel disease" 18 : 6782-6789, 2012

2 Schoepfer AM, "Ulcerative colitis : correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes" 15 : 1851-1858, 2009

3 Silverberg MS, "Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology" (19 Suppl A) : 5A-36A, 2005

4 Peyrin-Biroulet L, "Results from the 2nd Scientific Workshop of the ECCO. I. Impact of mucosal healing on the course of inflammatory bowel disease" 5 : 477-483, 2011

5 Bessissow T, "Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing" 107 : 1684-1692, 2012

6 Roseth AG, "Normalization of faecal calprotectin : a predictor of mucosal healing in patients with inflammatory bowel disease" 39 : 1017-1020, 2004

7 Sakuraba A, "Mucosal healing is associated with improved long-term outcome of maintenance therapy with natalizumab in Crohn’s disease" 19 : 2577-2583, 2013

8 Neurath MF, "Mucosal healing in inflammatory bowel diseases : a systematic review" 61 : 1619-1635, 2012

9 Froslie KF, "Mucosal healing in inflammatory bowel disease : results from a Norwegian population-based cohort" 133 : 412-422, 2007

10 Theede K, "Level of fecal calprotectin correlates with endoscopic and histologic inflammation and identifies patients with mucosal healing in ulcerative colitis" 13 : 1929-1936, 2015

11 Rosenberg L, "Histologic markers of inflammation in patients with ulcerative colitis in clinical remission" 11 : 991-996, 2013

12 Sipponen T, "Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn’s disease" 14 : 1392-1398, 2008

13 Schoepfer AM, "Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes" 19 : 332-341, 2013

14 Lasson A, "Fecal calprotectin levels predict the clinical course in patients with new onset of ulcerative colitis" 19 : 576-581, 2013

15 D’Haens G, "Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease" 18 : 2218-2224, 2012

16 Sipponen T, "Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease" 50 : 74-80, 2015

17 Schoepfer AM, "Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn’s disease(SES-CD)than CRP, blood leukocytes, and the CDAI" 105 : 162-169, 2010

18 Sipponen T, "Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn’s disease treatment" 45 : 325-331, 2010

19 Wassell J, "Evaluation of the Quantum Blue rapid test for faecal calprotectin" 49 (49): 55-58, 2012

20 Ricanek P, "Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers" 46 : 1081-1091, 2011

21 Colombel JF, "Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis" 141 : 1194-1201, 2011

22 Best WR, "Development of a Crohn’s disease activity index : National Cooperative Crohn’s Disease Study" 70 : 439-444, 1976

23 Daperno M, "Development and validation of a new, simplified endoscopic activity score for Crohn’s disease : the SES-CD" 60 : 505-512, 2004

24 Schroeder KW, "Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis : a randomized study" 317 : 1625-1629, 1987

25 Xiang JY, "Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis" 14 : 53-57, 2008

26 D’Inca R, "Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease" 22 : 429-437, 2007

27 Denis MA, "Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn’s disease with normal C-reactive protein serum level" 13 : 1100-1105, 2007

28 Asgharpour A, "Adalimumab treatment in Crohn’s disease : an overview of long-term efficacy and safety in light of the EXTEND trial" 6 : 153-160, 2013

29 Lobaton T, "A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn’s disease" 7 : e641-e651, 2013

30 Lobaton T, "A new rapid quantitative test for fecal calprotectin predicts endoscopic activity in ulcerative colitis" 19 : 1034-1042, 2013